804 related articles for article (PubMed ID: 28205333)
1. Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study.
Bird P; Nicholls D; Barrett R; de Jager J; Griffiths H; Roberts L; Tymms K; McCloud P; Littlejohn G;
Int J Rheum Dis; 2017 Apr; 20(4):460-468. PubMed ID: 28205333
[TBL] [Abstract][Full Text] [Related]
2. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
Lutf A; Poil AR; Hammoudeh M
Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions.
Castrejón I; Dougados M; Combe B; Fautrel B; Guillemin F; Pincus T
J Rheumatol; 2016 Jul; 43(7):1285-91. PubMed ID: 27084913
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis: a prospective longitudinal inception cohort study.
Boman A; Brink M; Lundquist A; Hansson M; Mathsson-Alm L; Rönnelid J; Berglin E; Holmdahl R; Skriner K; Serre G; Klareskog L; Rantapää-Dahlqvist S
RMD Open; 2019; 5(2):e000946. PubMed ID: 31565241
[TBL] [Abstract][Full Text] [Related]
6. Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.
Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordström D; Canhão H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
Scand J Rheumatol; 2019 Jan; 48(1):17-23. PubMed ID: 30260261
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid factor as predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis: Results of a cohort study.
Santos-Moreno P; Sánchez G; Castro C
Medicine (Baltimore); 2019 Feb; 98(5):e14181. PubMed ID: 30702571
[TBL] [Abstract][Full Text] [Related]
8. Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort.
Mouterde G; Rincheval N; Lukas C; Daien C; Saraux A; Dieudé P; Morel J; Combe B
Arthritis Res Ther; 2019 Jun; 21(1):140. PubMed ID: 31171038
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis.
Yilmaz-Oner S; Ozen G; Can M; Atagunduz P; Direskeneli H; Inanc N
J Rheumatol; 2015 Nov; 42(11):2066-70. PubMed ID: 26472417
[TBL] [Abstract][Full Text] [Related]
10. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
[TBL] [Abstract][Full Text] [Related]
11. Only rheumatoid factor-positive subset of anti-citrullinated peptide/protein antibody-negative rheumatoid arthritis may seroconvert to anti-citrullinated peptide/protein antibody-positive.
Hiwa R; Ohmura K; Nakabo S; Terao C; Murakami K; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Hashimoto M; Furu M; Ito H; Fujii T; Mimori T
Int J Rheum Dis; 2017 Jun; 20(6):731-736. PubMed ID: 28198158
[TBL] [Abstract][Full Text] [Related]
12. Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritis.
Kuriya B; Schieir O; Lin D; Xiong J; Pope J; Boire G; Haraoui B; Thorne JC; Tin D; Hitchon C; Jamal S; Keystone E; Bykerk VP;
Clin Exp Rheumatol; 2017; 35(5):799-803. PubMed ID: 28339365
[TBL] [Abstract][Full Text] [Related]
13. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
[TBL] [Abstract][Full Text] [Related]
14. Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan.
Koga T; Okada A; Fukuda T; Hidaka T; Ishii T; Ueki Y; Kodera T; Nakashima M; Takahashi Y; Honda S; Horai Y; Watanabe R; Okuno H; Aramaki T; Izumiyama T; Takai O; Miyashita T; Sato S; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Origuchi T; Nakamura H; Aoyagi K; Eguchi K; Kawakami A;
PLoS One; 2017; 12(5):e0175281. PubMed ID: 28505163
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with time to diagnosis in early rheumatoid arthritis.
Barnabe C; Xiong J; Pope JE; Boire G; Hitchon C; Haraoui B; Carter Thorne J; Tin D; Keystone EC; Bykerk VP;
Rheumatol Int; 2014 Jan; 34(1):85-92. PubMed ID: 23989941
[TBL] [Abstract][Full Text] [Related]
16. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
[TBL] [Abstract][Full Text] [Related]
17. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound-detected activity in rheumatoid arthritis on methotrexate therapy: Which joints and tendons should be assessed to predict unstable remission?
Janta I; Valor L; De la Torre I; Martínez-Estupiñán L; Nieto JC; Ovalles-Bonilla JG; Martínez-Barrio J; Bello N; Hinojosa M; Montoro M; González CM; López-Longo J; Monteagudo I; Carreño L; Naredo E
Rheumatol Int; 2016 Mar; 36(3):387-96. PubMed ID: 26712373
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
[TBL] [Abstract][Full Text] [Related]
20. Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity.
Tymms K; Zochling J; Scott J; Bird P; Burnet S; de Jager J; Griffiths H; Nicholls D; Roberts L; Arnold M; Littlejohn G
Arthritis Care Res (Hoboken); 2014 Feb; 66(2):190-6. PubMed ID: 23983001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
